Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Hollywood, Florida, United States, 33024
- CenExel RCA
-
Sunrise, Florida, United States, 33351
- Precision Clinical Research
-
-
Georgia
-
Savannah, Georgia, United States, 31406
- Meridian Clinical Research
-
-
Indiana
-
Valparaiso, Indiana, United States, 46383
- Velocity Clinical Research
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Johnson County Clin-Trials
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Benchmark Research
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- Alliance for Multispecialty Research
-
-
New York
-
Rochester, New York, United States, 14609
- Rochester Clinical Research
-
-
North Carolina
-
Wilmington, North Carolina, United States, 28401
- Acellacare of Wilmington
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- Velocity Clinical Research
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29405
- Coastal Carolina Research
-
-
Texas
-
San Angelo, Texas, United States, 76904
- Benchmark Research
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- JBR Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female age 18 to 49 years (inclusive) for the Phase 1 group, or 50 to 64 years (inclusive) for the Phase 2 group at the time of enrollment into the study.
- Able and willing to complete the informed consent process.
- Available for clinical follow-up through the last study visit at 6 months after the study vaccination.
- In good general health as determined by medical history, vital signs, physical examination, and clinical judgment of the investigator.
- Screening laboratory values must be within the central laboratory normal limits prior to study enrollment. Minor abnormalities are considered acceptable if not clinically significant.
- Willing to have blood samples collected, stored indefinitely, and used for research purposes.
- Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process.
- Negative pregnancy test (urine and serum) for women of childbearing potential.
Exclusion Criteria:
- Previous pneumococcal disease (either confirmed or by self-reporting).
- Previous receipt of a licensed or investigational pneumococcal vaccine.
- Receipt of any investigational study product within 30 days prior to enrollment into the study, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.
- Planned or actual administration of any licensed vaccine during the period starting 30 days before enrollment into the study through Day 29.
- Physical examination indicating any clinically significant medical condition.
- Body Temperature > 38.0°C (> 100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescheduled).
- Seropositive to HIV, HCV, or HBsAg.
- History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis.
- Female who is breast-feeding or planning to become pregnant during study participation.
- Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
- Any other chronic or clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject or confound evaluation of the study vaccine.
- Any medical, psychiatric, or social condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent.
- Received blood or blood product (including Immune Globulin IV) within 90 days prior to enrollment into the study.
- Received systemic corticosteroids for ≥ 14 consecutive days and has not completed treatment ≤30 days prior to enrollment into the study.
- Receiving immunosuppressive therapy.
- History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: VAX-24 Low Dose
Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1.
|
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
|
|
Experimental: VAX-24 Mid Dose
Participants will receive a single dose of VAX-24 2.2 mcg administered as an intramuscular injection on Day 1.
|
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
|
|
Experimental: VAX-24 Mixed Dose
Participants will receive a single dose of VAX-24 2.2 mcg/4.4
mcg administered as an intramuscular injection on Day 1.
|
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
|
|
Active Comparator: PCV20
Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
|
0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group
Time Frame: 7 days after vaccination
|
Solicited local reactions include redness/erythema, swelling/induration, and pain at injection site within 7 days after vaccination in each age group
|
7 days after vaccination
|
|
Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group
Time Frame: 7 days after vaccination
|
Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain
|
7 days after vaccination
|
|
Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group
Time Frame: 1 month after vaccination
|
Percentage of participants in each age group with adverse events (AEs) whose date of onset occurs after the study vaccine and within the 28 days after vaccination.
|
1 month after vaccination
|
|
Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI)
Time Frame: 6 months after vaccination
|
Percentage of participants with SAEs and NOCIs
|
6 months after vaccination
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values
Time Frame: 1 month after vaccination
|
Shifts from Normal at Baseline to Abnormal on Day 29 in Clinical Chemistry Parameters Occurring in >5% of Subjects Aged 50 to 64 Years
|
1 month after vaccination
|
|
VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs)
Time Frame: 1 month after vaccination
|
Antibody geometric mean titers as measured by OPA for the 24 pneumococcal serotypes in VAX-24
|
1 month after vaccination
|
|
VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs)
Time Frame: 1 month after vaccination
|
Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24
|
1 month after vaccination
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Development, Vaxcyte, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VAX24-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.